<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551173</url>
  </required_header>
  <id_info>
    <org_study_id>CXUO320BCN01</org_study_id>
    <nct_id>NCT01551173</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia</brief_title>
  <official_title>A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is to demonstrate therapeutic comparability of Fluvastatin sodium Extended Release
      Tablets 80 mg QD and Fluvastatin sodium Immediate Release Capsules 40 mg BID in LDL-C
      lowering from baseline to week 12 (endpoint) in patients with primary hypercholesterolemia or
      mixed dyslipidemia at moderate or high CV risk who did not achieve their lipid goals when
      treated with Fluvastatin sodium Immediate Release Capsules 40 mg QD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change in LDL-C From Baseline at Study Endpoint, Week 12 (LOCF)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>After the patient has been sitting for at least 5 minutes, a 12 hour fasting blood sample will be withdrawn at baseline and endpoint. An analysis of covariance (ANCOVA) with treatment, center, and indication category as factors and baseline LDL-C as a covariate will be used to analyze percent change from baseline in LDL-C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 4, Week 8, Week 12, and Endpoint for Lipid Variables Low Density Lipoprotein Cholesterol (LDL-C) , Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C) , Non HDL-C, Triglycerides (TG)</measure>
    <time_frame>Baseline, week 4, week 8, week 12, Endpoint</time_frame>
    <description>After the patient has been sitting for at least 5 minutes, a 12 hour fasting blood sample will be withdrawn. An analogous ANCOVA model to that used in the analysis of the primary variable will be used to compare the change in LDL-C, TC, HDL-C, non HDL-C and TG from baseline between treatment groups at Week 4, Week 8, and Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving Their LDL-C Treatment Goals at Week 4, Week 8, Week 12, and Endpoint</measure>
    <time_frame>Baseline, week 4, week 8, week 12, Endpoint</time_frame>
    <description>LDL-C treatment goal is defined as patients at moderate CV risk with LDL-C levels &lt; 3.37 mmol/L (130 mg/dL) or patients at high CV-risk with LDL-C levels &lt; 2.59 mmol/L (100 mg/dL). The proportion of patients in each treatment group achieving their LDL-C goal during the double-blind period will be compared at Week 4, Week 8, Week 12 and Endpoint using a logistic regression model with treatment and center as factors and baseline LDL-C as a covariate. Odds ratio estimates derived from the logistic regression model and 95%CI will be used to quantify the treatment effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Lipid Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Fluvastatin sodium Extended Release Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvastatin sodium Immediate Release Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin sodium</intervention_name>
    <description>Fluvastatin sodium Extended Release Tablets 80mg</description>
    <arm_group_label>Fluvastatin sodium Extended Release Tablet</arm_group_label>
    <arm_group_label>Fluvastatin sodium Immediate Release Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary hypercholesterolemia or mixed dyslipidemia at moderate or high
             CV risk according to Chinese Dyslipidemia Guideline (2007).

          -  Not having achieved lipid treatment goals despite following a cholesterol restrictive
             diet and/or lipid lowering monotherapy improperly prior to Visit 1 (inclusion in the
             6-week open-label study phase).

          -  Not having achieved lipid treatment goals on a stable dose of Fluvastatin sodium
             Immediate Release Capsule 40 mg QD during the 6 week open-label study phase (inclusion
             in the 12-week double-blind study phase).

        Exclusion Criteria:

          -  Patients with known hypersensitivity to fluvastatin or any of the excipients.

          -  Dyslipidemia secondary to other causes.

          -  Known muscle disease or history of muscle disease and/or serum CPK levels greater than
             2 x upper limit of normal (ULN).

          -  A history or evidence of Acute Myocardial infarction (AMI), unstable angina (UA) or
             Coronary artery bypass surgery or Percutaneous Coronary Intervention (PCI) within the
             previous 8 weeks.

          -  Active liver disease and/or serum transaminase levels (ALT, AST) greater than 1.5 x
             ULN.

          -  Patients on a proper lipid lowering monotherapy (defined as at least 12 weeks
             continuous monotherapy with a recommended dose and administration in the label) within
             the previous 3 months prior to visit 1.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>May 13, 2014</results_first_submitted>
  <results_first_submitted_qc>May 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2014</results_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemias</keyword>
  <keyword>Fluvastatin sodium</keyword>
  <keyword>Chinese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluvastatin Sodium Extended Release Tablet</title>
          <description>Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Fluvastatin Sodium Immediate Release Capsule</title>
          <description>Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="218">&quot;Started&quot; indicates randomized</participants>
                <participants group_id="P2" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="210">Patients took at least 1 dose of study drug &amp; had at least 1 post-randomization efficacy parameter</participants>
                <participants group_id="P2" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set (RAN)</population>
      <group_list>
        <group group_id="B1">
          <title>Fluvastatin Sodium Extended Release Tablet</title>
          <description>Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Fluvastatin Sodium Immediate Release Capsule</title>
          <description>Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="218"/>
            <count group_id="B2" value="218"/>
            <count group_id="B3" value="436"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="8.39"/>
                    <measurement group_id="B2" value="60.4" spread="9.30"/>
                    <measurement group_id="B3" value="59.6" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in LDL-C From Baseline at Study Endpoint, Week 12 (LOCF)</title>
        <description>After the patient has been sitting for at least 5 minutes, a 12 hour fasting blood sample will be withdrawn at baseline and endpoint. An analysis of covariance (ANCOVA) with treatment, center, and indication category as factors and baseline LDL-C as a covariate will be used to analyze percent change from baseline in LDL-C.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>FAS: all randomized patients who received at least one dose of double-blind study medication and one post-randomization efficacy parameter measurement. The intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. Endpoint: final available post-baseline assessment to last scheduled visit</population>
        <group_list>
          <group group_id="O1">
            <title>Fluvastatin Sodium Extended Release Tablet</title>
            <description>Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fluvastatin Sodium Immediate Release Capsule</title>
            <description>Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in LDL-C From Baseline at Study Endpoint, Week 12 (LOCF)</title>
          <description>After the patient has been sitting for at least 5 minutes, a 12 hour fasting blood sample will be withdrawn at baseline and endpoint. An analysis of covariance (ANCOVA) with treatment, center, and indication category as factors and baseline LDL-C as a covariate will be used to analyze percent change from baseline in LDL-C.</description>
          <population>FAS: all randomized patients who received at least one dose of double-blind study medication and one post-randomization efficacy parameter measurement. The intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. Endpoint: final available post-baseline assessment to last scheduled visit</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.692" spread="1.4229"/>
                    <measurement group_id="O2" value="-7.887" spread="1.4258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 4, Week 8, Week 12, and Endpoint for Lipid Variables Low Density Lipoprotein Cholesterol (LDL-C) , Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C) , Non HDL-C, Triglycerides (TG)</title>
        <description>After the patient has been sitting for at least 5 minutes, a 12 hour fasting blood sample will be withdrawn. An analogous ANCOVA model to that used in the analysis of the primary variable will be used to compare the change in LDL-C, TC, HDL-C, non HDL-C and TG from baseline between treatment groups at Week 4, Week 8, and Week 12</description>
        <time_frame>Baseline, week 4, week 8, week 12, Endpoint</time_frame>
        <population>FAS: all randomized patients who received at least one dose of double-blind study medication and one post-randomization efficacy parameter measurement. The intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. Endpoint: final available post-baseline assessment to last scheduled visit</population>
        <group_list>
          <group group_id="O1">
            <title>Fluvastatin Sodium Extended Release Tablet</title>
            <description>Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fluvastatin Sodium Immediate Release Capsule</title>
            <description>Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 4, Week 8, Week 12, and Endpoint for Lipid Variables Low Density Lipoprotein Cholesterol (LDL-C) , Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C) , Non HDL-C, Triglycerides (TG)</title>
          <description>After the patient has been sitting for at least 5 minutes, a 12 hour fasting blood sample will be withdrawn. An analogous ANCOVA model to that used in the analysis of the primary variable will be used to compare the change in LDL-C, TC, HDL-C, non HDL-C and TG from baseline between treatment groups at Week 4, Week 8, and Week 12</description>
          <population>FAS: all randomized patients who received at least one dose of double-blind study medication and one post-randomization efficacy parameter measurement. The intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. Endpoint: final available post-baseline assessment to last scheduled visit</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C week 4 (n=210,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.447" spread="0.0427"/>
                    <measurement group_id="O2" value="-0.438" spread="0.0426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C week 8 (n=193,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.418" spread="0.0460"/>
                    <measurement group_id="O2" value="-0.408" spread="0.0465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C week 12 (n=192,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.353" spread="0.0475"/>
                    <measurement group_id="O2" value="-0.377" spread="0.0485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C Endpoint (n=210,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.339" spread="0.0483"/>
                    <measurement group_id="O2" value="-0.298" spread="0.0484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC week 4 (n=205,211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.450" spread="0.0497"/>
                    <measurement group_id="O2" value="-0.457" spread="0.0495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC week week 8 (n=193,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.409" spread="0.0497"/>
                    <measurement group_id="O2" value="-0.419" spread="0.0503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC week 12 (n=192,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.314" spread="0.0531"/>
                    <measurement group_id="O2" value="-0.376" spread="0.0542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC Endpoint (n=210,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.294" spread="0.0548"/>
                    <measurement group_id="O2" value="-0.290" spread="0.0549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C week 4 (n=205,211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.0118"/>
                    <measurement group_id="O2" value="0.002" spread="0.0118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C week 8 (n=193,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.0128"/>
                    <measurement group_id="O2" value="0.016" spread="0.0130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C week 12 (n=192,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.0129"/>
                    <measurement group_id="O2" value="0.010" spread="0.0132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C Endpoint (n=210,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.0123"/>
                    <measurement group_id="O2" value="0.012" spread="0.0124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non HDL-C week 4 (n=205,211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.447" spread="0.0488"/>
                    <measurement group_id="O2" value="-0.461" spread="0.0487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non HDL-C week 8 (n=193,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.422" spread="0.0484"/>
                    <measurement group_id="O2" value="-0.438" spread="0.0490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non HDL-C week 12 (192,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.350" spread="0.0528"/>
                    <measurement group_id="O2" value="-0.388" spread="0.0540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-HDL Endpoint (n=210,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.325" spread="0.0550"/>
                    <measurement group_id="O2" value="-0.305" spread="0.0551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG week 4(n=205,211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.0550"/>
                    <measurement group_id="O2" value="-0.096" spread="0.0554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG week 8 (n=193,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.065" spread="0.0373"/>
                    <measurement group_id="O2" value="-0.134" spread="0.0381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG week 12 (n=192,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.0498"/>
                    <measurement group_id="O2" value="-0.124" spread="0.0514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG Endpoint (n=210,214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" spread="0.0559"/>
                    <measurement group_id="O2" value="-0.088" spread="0.0566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving Their LDL-C Treatment Goals at Week 4, Week 8, Week 12, and Endpoint</title>
        <description>LDL-C treatment goal is defined as patients at moderate CV risk with LDL-C levels &lt; 3.37 mmol/L (130 mg/dL) or patients at high CV-risk with LDL-C levels &lt; 2.59 mmol/L (100 mg/dL). The proportion of patients in each treatment group achieving their LDL-C goal during the double-blind period will be compared at Week 4, Week 8, Week 12 and Endpoint using a logistic regression model with treatment and center as factors and baseline LDL-C as a covariate. Odds ratio estimates derived from the logistic regression model and 95%CI will be used to quantify the treatment effect.</description>
        <time_frame>Baseline, week 4, week 8, week 12, Endpoint</time_frame>
        <population>FAS: all randomized patients who received at least one dose of double-blind study medication and one post-randomization efficacy parameter measurement. The intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. Endpoint: final available post-baseline assessment to last scheduled visit</population>
        <group_list>
          <group group_id="O1">
            <title>Fluvastatin Sodium Extended Release Tablet</title>
            <description>Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fluvastatin Sodium Immediate Release Capsule</title>
            <description>Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving Their LDL-C Treatment Goals at Week 4, Week 8, Week 12, and Endpoint</title>
          <description>LDL-C treatment goal is defined as patients at moderate CV risk with LDL-C levels &lt; 3.37 mmol/L (130 mg/dL) or patients at high CV-risk with LDL-C levels &lt; 2.59 mmol/L (100 mg/dL). The proportion of patients in each treatment group achieving their LDL-C goal during the double-blind period will be compared at Week 4, Week 8, Week 12 and Endpoint using a logistic regression model with treatment and center as factors and baseline LDL-C as a covariate. Odds ratio estimates derived from the logistic regression model and 95%CI will be used to quantify the treatment effect.</description>
          <population>FAS: all randomized patients who received at least one dose of double-blind study medication and one post-randomization efficacy parameter measurement. The intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization. Endpoint: final available post-baseline assessment to last scheduled visit</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate cardiovascular risk at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate cardiovascular risk at week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate cardiovascular risk at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate cardiovascular risk Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high cardiovascular risk at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high cardiovascular risk at week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high cardiovascular risk at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>high cardiovascular risk at Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LescolXL (Fluvastatin Sodium Extended Release Tablet)</title>
          <description>Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>LescolIR (Fluvastatin Sodium Immediate Release Capsule)</title>
          <description>Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug administration error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Rectal polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

